Multiple Myeloma Clinical Trials

167 studies are recruiting for multiple myeloma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 6

1. Elranatamab in Relapsed/Refractory Multiple Myeloma

   This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California San Diego, La Jolla, California

   Run by

   University of California, San Diego

   See if you can join NCT06711705 on ClinicalTrials.gov

2. A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

   This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   11 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07225738 on ClinicalTrials.gov

3. Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

   This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey

   Run by

   Hackensack Meridian Health

   See if you can join NCT03909412 on ClinicalTrials.gov

4. Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

   This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.

   Stage

   Phase 1

   Ages

   19 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   Susan Bal

   See if you can join NCT07333261 on ClinicalTrials.gov

5. In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

   The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans ce…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05093335 on ClinicalTrials.gov

6. Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

   This is a single-arm, open-label phase II study with a safety lead-in phase.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

   Run by

   Medical College of Wisconsin

   See if you can join NCT04240054 on ClinicalTrials.gov

7. Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

   The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder suc…

   Stage

   Not phased

   Ages

   Any age

   Site

   Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

   Locations

   6 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT00582621 on ClinicalTrials.gov

8. Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

   The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior to receiving autologous stem cell transplant (ASCT) for multiple myeloma participants will improve muscular strength, ph…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT05706766 on ClinicalTrials.gov

9. Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

   The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.

   Stage

   Not phased

   Ages

   Any age

   Site

   Ut Southwestern, Dallas, Texas

   Locations

   8 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06357754 on ClinicalTrials.gov

10. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

    Stage

    Not phased

    Ages

    40 and older

    Site

    City of Hope, Duarte, California

    Locations

    17 in total

    Run by

    Adela, Inc

    See if you can join NCT05366881 on ClinicalTrials.gov

11. Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

    The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT05922501 on ClinicalTrials.gov

12. Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

    The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1. Get rid of any residual multiple myeloma cells in participants' bodies which is known as minimal residual disease negative (MRD-) stat…

    Stage

    Phase 2

    Ages

    Any age

    Site

    University of Miami, Miami, Florida

    Run by

    Dickran Kazandjian, MD

    See if you can join NCT06910124 on ClinicalTrials.gov

13. Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

    This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma (cohort A) and amyloidosis (cohort B).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT04991103 on ClinicalTrials.gov

14. Prehabilitation Feasibility Among Older Adults Undergoing Transplantation

    This is a pilot feasibility trial among older adults (≥60y) scheduled to undergo Autologous Stem Cell transplantation at UAB. Participants will be randomized into either a prehabilitation program or an attention control group before their transplant. The primary outcomes will be feasibility and sec…

    Stage

    Not phased

    Ages

    60 and older

    Site

    Kirklin Clinic of UAB Hospital, Birmingham, Alabama

    Run by

    Noha Mohamed Sharafeldin

    See if you can join NCT05642884 on ClinicalTrials.gov

15. Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

    Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple my…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT05789303 on ClinicalTrials.gov

16. Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

    A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Illinois Cancer Center, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT05192122 on ClinicalTrials.gov

17. Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

    The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) *…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Omar Nadeem, MD

    See if you can join NCT06518551 on ClinicalTrials.gov

18. Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

    The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at …

    Stage

    Not phased

    Ages

    50 and older

    Site

    Kirklin Clinic of UAB Hospital, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT05556928 on ClinicalTrials.gov

19. Collection of Samples and Clinical Data From Patients With Amyloid Diseases

    RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future. PURPOSE: This research study is collecting samples from patients with amyloid diseases

    Stage

    Not phased

    Ages

    18 and older

    Site

    Boston University Cancer Research Center, Boston, Massachusetts

    Run by

    Boston Medical Center

    See if you can join NCT00898235 on ClinicalTrials.gov

20. Mozobil for Autologous Hematopoietic Stem Cell Transplantation

    This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT07188090 on ClinicalTrials.gov

21. Registry for Adults With Plasma Cell Disorders (PCD's)

    The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives includ…

    Stage

    Not phased

    Ages

    18 and older

    Site

    North Carolina Cancer Hospital, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT03717844 on ClinicalTrials.gov

22. A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

    The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermine…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06055894 on ClinicalTrials.gov

23. Long-term Follow-up Study of Patients Receiving CAR-T Cells

    This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refracto…

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT03375619 on ClinicalTrials.gov

24. Sleep Apnea in Patients With MGUS and MM

    This study involves patients with plasma cell dyscrasia including monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM), with and without sleep apnea, who are providing bone marrow specimens. Specimens will be obtained at the time that patients undergo a standard-of-car…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    University of Iowa, Iowa City, Iowa

    Run by

    Michael Tomasson

    See if you can join NCT04114084 on ClinicalTrials.gov

25. Two Step Haplo With Radiation Conditioning

    This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT05031897 on ClinicalTrials.gov